Molecular Diagnostics Market Size, Share, Growth and Forecast, 2025-2035

Rapid PCR moves gene-level testing closer to patients

The global molecular diagnostics market was valued at USD 17.97 billion in 2025 and is projected to increase from USD 19.22 billion in 2026 to USD 35.15 billion by 2035, registering a CAGR of 6.94% during 2026–2035. Demand comes from hospital and reference laboratories, clinics, blood banks and public health programs that detect DNA and RNA to diagnose infections, guide cancer therapy and screen for inherited conditions. North America held the largest regional share, 41.0% in 2025, because high test volumes, insurance coverage and large reference labs support spending. Asia Pacific is the fastest-growing region at 8.21% a year, as China and India expand hospital laboratories and public screening. The main change is the move of PCR testing out of central labs, with CLIA-waived systems for clinics and the first nonprescription home test for three sexually transmitted infections cleared in the U.S. in 2025.

Which tests and products count toward market value?

The market counts manufacturer revenue from instruments, test kits and consumables used to detect nucleic acids in patient samples. It covers polymerase chain reaction, in situ hybridization, isothermal amplification and other methods such as sequencing and microarrays. Buyers include hospital labs, independent reference labs, clinics, blood banks and consumers who run approved home tests.

Kits account for most value, because each installed analyzer consumes reagents for every sample over many years of use. The scope excludes laboratory service fees billed to patients, research-only reagents and protein-based immunoassays, and the value chain runs from assay developers and instrument makers through distributors to labs and clinics.

Kits, lab testing and PCR lead molecular test spending

Why do kits earn most molecular test revenue?

Based on product, the market is categorized into instrument, kits and consumables. Kits led with a 58.0% share of 2025 value and also grow fastest at 7.23% a year. This lead reflects the installed-base model, because labs place PCR and sequencing systems under long contracts and then buy assays and controls for every sample. As a result, kit revenue rises with test volumes even when instrument orders slow.

Why does point-of-contact testing grow faster than lab testing?

Based on test type, the market is categorized into lab and point of contact. Lab testing led with a 78.0% share of 2025 value, because hospital and reference labs run high-throughput PCR and sequencing. Point of Contact testing grows fastest at 8.70% a year, as CLIA-waived systems and home tests let clinics and patients get PCR results in the same visit.

Why does PCR keep the lead among technologies?

Based on technology, the market is categorized into polymerase chain reaction, in situ hybridization, INAAT and others. Polymerase Chain Reaction led with a 52.0% share of 2025 value, because real-time PCR offers high sensitivity for infections and cancer markers. INAAT grows fastest at 8.08% a year, as isothermal methods need simpler hardware for near-patient use.

Why do infectious diseases lead application spending?

Based on application, the market is categorized into infectious diseases, oncology, genetic testing, cardiovascular disease, microbiology and others. Infectious Diseases led with a 44.0% share of 2025 value, because respiratory, sexually transmitted and bloodborne infections drive high volumes. Oncology grows fastest at 8.11% a year, as tumor profiling and liquid biopsy tests move into routine care.

Infection control, cancer care and faster answers

Why does infectious disease testing anchor demand?

Infections such as tuberculosis, HIV, hepatitis and sexually transmitted diseases need accurate nucleic acid tests before treatment begins, which keeps PCR demand high in every health system. The WHO reports that 8.2 million people were newly diagnosed with TB in 2023, a record since global monitoring began in the mid-1990s. However, only 62% of pulmonary new and relapse cases were bacteriologically confirmed that year. As a result, rapid molecular tests remain a priority for ministries of health and donor programs through 2035.

How do same-visit results change clinical decisions?

Clinicians want answers while patients are still in the clinic, which lets them start treatment before people leave. In January 2025, Roche announced FDA clearance with CLIA waiver for cobas liat tests for sexually transmitted infections, with PCR results in 20 minutes or less. Cepheid also received FDA authorization with CLIA waiver for its Xpert HCV fingerstick test in June 2024, with results in about an hour. Because these systems need minimal training, point-of-care testing now reaches urgent care and community health sites.

Download Free Sample

Why do precision oncology and sequencing lift test value?

Cancer care increasingly depends on gene tests that select targeted therapies and track recurrence, and these tests carry higher prices than routine infection panels. Labs use PCR, in situ hybridization and next-generation sequencing to profile tumors for mutations, fusions and amplifications. As more targeted drugs reach the market, oncologists order biomarker tests earlier in treatment. In turn, oncology adds value faster than test volumes and grows fastest among applications through 2035, with tumor profiling ordered at diagnosis and again at relapse.

How do syndromic panels raise test value per patient?

Hospitals are replacing single-pathogen tests with syndromic PCR panels that check many respiratory, gastrointestinal or bloodstream pathogens from one sample. QIAGEN announced U.S. clearance of the higher-throughput QIAstat-Dx Rise in September 2025, a system that processes up to 160 samples a day across eight modules. Because each panel replaces several separate tests, it raises revenue per sample. This shift also supports antibiotic stewardship programs in many hospitals, because doctors can stop broad drugs sooner.

Home PCR, syndromic panels and ownership changes

Why is home PCR testing rising?

Consumers became used to testing at home during the pandemic, and regulators now clear home molecular tests for other infections. On March 28, 2025, the FDA granted marketing authorization to the first home test for chlamydia, gonorrhea and trichomoniasis sold without a prescription. This rise gives point-of-contact testing the fastest growth between test types through 2035. In turn, makers of compact PCR cartridges are building retail and online sales channels.

How are ownership changes reshaping suppliers?

Large groups are separating or selling diagnostics units, which shifts investment priorities across the field. BD completed the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation in February 2026. Blackstone and TPG then completed their acquisition of Hologic on April 7, 2026, taking the women's health and molecular test maker private. As a result, buyers will watch how new owners fund assay menus and service networks.

Download Free Sample

Where is the opening in tuberculosis and emerging markets?

Rapid molecular testing for tuberculosis, HIV and hepatitis in Asia, Africa and Latin America is a clear opening, because many patients are still diagnosed by older methods. WHO data show that bacteriological confirmation of pulmonary TB was only 55% in the Eastern Mediterranean Region and 58% in the Western Pacific Region in 2023. Companies that offer low-cost cartridges, durable instruments and local service can capture this growth.

Can lab-developed tests open room for specialty labs?

Rules for lab-developed tests in the U.S. changed in 2025, which gives specialty labs more room to launch new molecular assays. A federal court vacated the FDA rule on these tests on March 31, 2025, and the FDA rescinded its 2024 rule in September 2025. This opening helps academic and reference labs build oncology and genetic panels faster. However, labs must still meet existing quality standards and payer evidence requirements.

Post-pandemic resets, pricing and rule changes

How does the post-pandemic reset weigh on PCR sales?

COVID-19 testing created a sharp spike in molecular test revenue during 2020 to 2022, followed by a steep decline. Many labs still hold excess PCR capacity, which slows new instrument orders in some regions. Manufacturers have therefore shifted their menus toward respiratory panels, sexually transmitted infections and oncology. This transition takes time, because each new assay needs clinical studies and regulatory clearance before launch. Suppliers that built broad menus early have recovered faster than those that relied on COVID-19 tests.

Why does reimbursement pressure limit value growth?

Public and private payers often question the price of multi-pathogen panels and gene tests, which limits coverage for some assays. Labs respond by restricting panel use to patients with clear clinical need. As a result, value growth in some infection panels trails volume growth. Manufacturers offset this pressure with outcome studies, smaller targeted panels and automation that lowers cost per test. In turn, labs that show fewer repeat tests and shorter hospital stays win better coverage terms.

How do regulatory differences add cost for assay makers?

Assay makers must meet different rules in the U.S., the European Union, China and other markets, which raises the cost of each launch. Tighter conformity requirements in Europe add clinical evidence and documentation needs for many molecular tests. Shifting U.S. rules for lab-developed tests also make long-term planning harder. Companies must therefore fund regulatory teams that track several regimes at once. Smaller assay developers feel this burden most, so many seek partners with global regulatory reach.

Why do skilled staff shortages slow adoption?

Many hospitals and reference labs report shortages of trained laboratory scientists, which limits how many molecular tests they can run each day. Sequencing and in situ hybridization still need skilled staff for sample preparation and result review. These gaps delay the launch of complex assays in smaller labs. In turn, buyers favor fully automated sample-to-answer systems, although such systems cost more per test. Training programs for laboratory scientists also take several years to expand capacity.

U.S. labs lead as Asian testing capacity expands

North America leads on reference lab volumes

North America held a 41.0% share of 2025 value and grows at 6.51% a year through 2035. The U.S. leads spending, because large reference labs process high volumes of infection, oncology and genetic tests. CLIA-waived and nonprescription clearances in 2025 extend PCR into retail clinics and homes. However, payer limits on large panels hold down value growth for some assays. The WHO reports that 81% of pulmonary TB cases in the Americas were bacteriologically confirmed in 2023, the highest rate among WHO regions.

Europe balances tenders and conformity costs

Europe held a 27.0% share of 2025 value and grows at 6.21% a year, the slowest pace among the five regions. Germany, France, Italy, Spain and the U.K. account for most demand, with hospital groups buying through competitive tenders. As a result, labs run high volumes at lower prices per test, while manufacturers carry added conformity costs for each assay. WHO data show that 70% of pulmonary TB cases in the European Region were bacteriologically confirmed in 2023.

Download Free Sample

Asia Pacific grows on lab expansion and screening

Asia Pacific held a 23.0% share of 2025 value and is the fastest-growing region at 8.21% a year. China and India are building hospital laboratories and public screening programs, while Japan and South Korea keep high use of oncology and genetic tests. Local manufacturers compete on price in China through volume-based procurement. In turn, global suppliers focus on premium syndromic and oncology menus, as only 60% of pulmonary TB cases in South-East Asia were bacteriologically confirmed in 2023.

Latin America relies on private laboratory chains

Latin America held a 5.0% share of 2025 value and grows at 7.41% a year through 2035. Brazil and Mexico account for most demand, where private laboratory chains run large networks of collection centers. Currency swings and public budget limits slow the purchase of new PCR systems.

Middle East and Africa build molecular capacity

The Middle East & Africa held a 4.0% share of 2025 value and grows at 7.71% a year. Gulf states invest in national genomic programs and new hospital laboratories. In much of Africa, donor-funded programs drive demand for HIV and tuberculosis molecular tests.

Download Free Sample

Clearances and deals in molecular testing, 2024 to 2026

Isothermal methods and automation cut time to result

• CLIA-waived PCR systems such as cobas liat deliver results in 20 minutes or less at clinics with minimal staff training.
• Syndromic PCR panels detect many pathogens from one sample, and the QIAstat-Dx Rise returns results in about one hour.
• Isothermal amplification copies DNA or RNA at a single temperature, which allows smaller and cheaper instruments.
• Fingerstick molecular tests such as Xpert HCV detect viral RNA from a small blood sample in about an hour.
• Sample-to-answer automation combines extraction, amplification and detection in one cartridge, which reduces staff time per test.

Platform makers compete on menus and installed base

Competition in molecular diagnostics rests on installed instruments, broad assay menus and long reagent contracts. Danaher, through Cepheid and Abbott compete across infection testing with rapid and high-throughput PCR systems. QIAGEN and bioMérieux SA focus on sample preparation and syndromic panels, while Hologic leads in women's health assays and became a private company in April 2026. Illumina supplies sequencing systems for oncology and genetic testing, and Agilent Technologies offers in situ hybridization and cancer test products. Siemens Healthineers, Sysmex and Bio-Rad Laboratories compete in lab systems, oncology tests and quality controls. BD moved its diagnostic solutions business to Waters in February 2026. Because labs rarely switch platforms, suppliers gain share mostly through new menus and acquisitions.

Companies profiled and their roles in this market

Assay menus beyond COVID-19 carry growth to 2035

Credence Research's view is that assay menus beyond COVID-19 will carry most of the value growth in molecular diagnostics through 2035. Infectious disease panels keep the volume base, but oncology adds value faster as tumor profiling and blood-based tests spread. Point-of-contact testing gains share as regulators clear more CLIA-waived and home PCR tests. Ownership changes in 2026 show that investors value focused diagnostics businesses. Suppliers with large installed bases and broad menus are best placed to grow.

Test volumes and kit prices anchor the model

The report uses 2025 as the base year and forecasts market value to 2035, with growth rates stated for 2026–2035. Market values come from the Credence Research market model, which combines test volumes by application, installed instruments and average kit prices by region and test type. Splits by product, test type, technology, application and region are Credence Research estimates. Sources used include FDA announcements, WHO tuberculosis data, SEC filings and company press releases. No primary interviews or surveys were used to build the estimates in this report.

Near-patient PCR and oncology gain share by 2035

By 2035, the market reaches USD 35.15 billion, with kits still providing most of the value. Oncology gains share as tumor profiling moves into routine care, and point-of-contact testing grows faster than lab testing as home and clinic PCR spreads. Asia Pacific adds capacity as China and India expand hospital labs, while North America remains the largest region. Automation helps labs cope with staff shortages, and new owners reshape portfolios toward faster-growing menus. Isothermal methods and fingerstick tests extend molecular testing to community clinics in lower-income countries.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.